Baxter International (BAX) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Baxter International (BAX) has outperformed Stereotaxis (STXS) over the past year, gaining 5.1% versus a loss of 68.9%. Over five years, BAX leads with a -70.0% price change compared with -81.3% for STXS. Baxter International is the larger company by market cap ($12.36 billion vs $111.2 million), about 111.1 times the size.
Baxter International pays a dividend yielding 0.84%, while Stereotaxis does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BAX | STXS |
|---|---|---|
| Share price | $23.90 | $1.11 |
| Market cap | $12.36B | $111.22M |
| 1-day change | -0.29% | -1.77% |
| YTD return | +25.07% | -51.74% |
| 1-year return | +5.05% | -68.91% |
| 5-year return | -70.01% | -81.28% |
| Forward P/E | 11.72 | — |
| EPS (TTM) | $-1.88 | $-0.24 |
| Dividend yield | 0.84% | 0.00% |
| Annual dividend | $0.20 | $0.00 |
| Revenue (latest FY) | $11.24B | — |
| Revenue growth (YoY) | +5.72% | — |
| Net income (latest FY) | $-957.00M | — |
| Gross margin | 30.05% | — |
| Operating margin | -2.74% | — |
| Net margin | -8.51% | — |
| 52-week high | $30.00 | $3.42 |
| 52-week low | $15.73 | $1.09 |
| Distance from 52-week high | -20.33% | -67.54% |
| Analyst consensus | hold | none |
| Avg. price target upside | +16.82% | +170.27% |
| Average volume | 6.66M | 808.41K |
| Shares outstanding | 517.00M | 100.20M |
| Employees | 37,500 | 131 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Baxter International is about 111.1 times larger than Stereotaxis by market value ($12.36B vs $111.22M).
- BAX has outperformed STXS by 74.0 percentage points over the past year.
About Baxter International
BAX stock →Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
Health Care · Medical/Dental Instruments · 37,500 employees
About Stereotaxis
STXS stock →Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 131 employees
BAX vs STXS FAQ
Which is bigger, Baxter International or Stereotaxis?
Baxter International (BAX) is larger, with a market capitalization of $12.36B compared with $111.22M for Stereotaxis (STXS).
Which stock has performed better over the past year, BAX or STXS?
BAX returned +5.05% over the past 12 months, compared with -68.91% for STXS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Baxter International or Stereotaxis?
Baxter International pays a dividend yielding 0.84%, while Stereotaxis does not currently pay a regular dividend.
Are Baxter International and Stereotaxis in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Baxter International and Biotechnology: Electromedical & Electrotherapeutic Apparatus for Stereotaxis.